Recently, several clinical CAR T cell therapies have already been tested for GBM using epidermal growth factor receptor variant III (EGFRvIII), interleukin (IL)13Rα2 (IL-13Ra2), and ephrin-A2 (Her2) as targets, with mixed but informative results [120, 121]. This evidence concerns the gene IL13RA2 and glioblastoma.